全球**兔单株抗体蛋白生技厂Epitomics(F-宜佰)(4149-TW)，今(6)日宣布以1.7亿美元与英国上市公司全球蛋白研究工具领导供应商Abcam plc合并，由于公司已被Abcam合并，因此F-宜佰也将确定不在国内上柜。
EpitomicsF-宜佰表示，公司于100年3月2日签订并购合约。以总价美金1.7亿元元收购全数已发行股份，扣除原有现金1500万美元後，净交易价格为美金1.55亿元，价款支付方式将以50%现金及50%换股的方式完成。
EpitomicsF-宜佰成立于2001年，总部设于美国加州，资本额约3.62亿元台币，主要业务为兔单株抗体试剂及客制化委托服务，其中兔单株抗体营收占比50%，客制化抗体30%，另有15-20%来自技术授权的权利金，目前拥有兔单抗产品超过3千种，包括用于抗PEG、乳腺癌、帕金森氏症及老年痴呆体外检测等。目前客户群中95%全球跨国大厂，除罗氏外，尚有Pfizer、Amgen、P&G、拜耳等，其中已有6个抗体用于新药研发，其中3个进入人体临床的时程，只要客户有进展，就可以收钱且不用承担任何风险。
LONDON (MarketWatch) -- Abcam PLC , which supplies protein research tools, said Monday it has entered into a definitive agreement to buy Epitomics International Inc, an antibody business headquartered in San Francisco, California, with operations in China, for $170.0 million in cash and shares.
MAIN FACTS:
-At completion Epitomics is expected to have net cash of $15.0 million resulting in net consideration for the acquisition of $155.0 million.
-Acquisition is expected to close one to two months' time.
-New GBP20.0 million revolving credit facility put in place to part fund the acquisition.
-Abcam and Epitomics have agreed to a $10.0 million mutual break fee payable in certain circumstances if acquisition doesn't complete.
-Acquisition is expected to be earnings neutral in the first full year of ownership as Company invests in the business to expand production and accelerate growth.
-Acquisition is expected to be earnings enhancing in the second full year of ownership.
-In the year ended Dec. 31, 2011 Epitomics had unaudited revenue of $24.7 million, EBITDA of $7.6 million and profit before tax of $6.8 million; at Dec. 31 Epitomics had net assets of $30.0 million.
-Shares at 0905 GMT up 7 pence, or 2%, at 339 pence valuing the company at GBP609.85 million.